The role of nitric oxide and cGMP in somatostatin's protection against retinal ischemia

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 1, 2008, Pages 342-349

  Mastrodimou, Niki ^a   Kiagiadaki, Foteini ^a   Thermos, Kyriaki ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CHOLINE ACETYLTRANSFERASE; CYCLIC GMP; CYSTEINE; GUANYLATE CYCLASE INHIBITOR; LINSIDOMINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; SOMATOSTATIN; 3 MORPHOLINO SYDNONIMINE; 3-MORPHOLINO-SYDNONIMINE; 8 BROMO CYCLIC GMP; 8-BROMOCYCLIC GMP; ANGIOPEPTIN; CYCLOPEPTIDE; DRUG DERIVATIVE; ENZYME INHIBITOR; MOLSIDOMINE; SPERMINE; SPERMINE NITRIC OXIDE COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IMMUNOREACTIVITY; NEUROPROTECTION; NICK END LABELING; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; RETINA ISCHEMIA; SPRAGUE DAWLEY RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; ISCHEMIA; METABOLISM; PATHOLOGY; PHYSIOLOGY; RETINA BLOOD VESSEL; RETINA DISEASE;

ANIMALS; CHOLINE O-ACETYLTRANSFERASE; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IN SITU NICK-END LABELING; ISCHEMIA; MOLSIDOMINE; NITRIC OXIDE; PEPTIDES, CYCLIC; RATS; RATS, SPRAGUE-DAWLEY; RETINAL DISEASES; RETINAL VESSELS; SOMATOSTATIN; SPERMINE;

EID: 39549115094     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-0341     Document Type: Article

References (55)

1. Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:77-79.
2. Shapiro B, Kronheim S, Pimstone B. The presence of immunoreactive somatostatin in rat retina. Horm Metab Res. 1979;11:79-80.
3. Hoyer D, Bell GI, Berelowitz M, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci. 1995;16:86-88.
4. Thermos K. Functional mapping of somatostatin receptors in the retina: a review. Vision Res. 2003;43:1805-1815.
5. Helboe L, Moller M. Immunohistochemical localization of somatostatin receptor subtypes sst1 and sst2 in the rat retina. Invest Ophthalmol Vis Sci. 1999;40:2376-2382.
6. Johnson J, Wong H, Walsh JH, Brecha NC. Expression of the somatostatin subtype 2A receptor in the rabbit retina. J Comp Neurol. 1998;393:93-101.
7. Johnson J, Wu V, Wong H, Walsh JH, Brecha NC. Somatostatin receptor subtype 2A expression in the rat retina. Neuroscience. 1999;94:675-683.
8. Vasilaki A, Gardette R, Epelbaum J, Thermos K. NADPH-diaphorase colocalization with somatostatin receptor subtypes sst2A and sst2B in the retina. Invest Ophthalmol Vis Sci. 2001;42:1600-1609.
9. Petrucci C, Resta V, Fieni F, Bigiani A, Bagnoli P. Modulation of potassium current and calcium influx by somatostatin in rod bipolar cells isolated from the rabbit retina via sst2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:680-694.
10. Vasilaki A, Papadaki T, Notas G, et al. Effect of somatostatin on nitric oxide production in human retinal pigment epithelium cell cultures. Invest Ophthalmol Vis Sci. 2004;45:1499-1506.
11. Cristiani R, Fontanesi G, Casini G, Petrucci C, Viollet C, Bagnoli P. Expression of somatostatin subtype 1 receptor in the rabbit retina. Invest Ophthalmol Vis Sci. 2000;41:3191-3199.
12. Vasilaki A, Mouratidou M, Schulz S, Thermos K. Somatostatin mediates nitric oxide production by activating sst(2) receptors in the rat retina. Neuropharmacology. 2002;43:899-909.
13. Cristiani R, Petrucci C, Dal Monte M, Bagnoli P. Somatostatin (SRIF) and SRIF receptors in the mouse retina. Brain Res. 2002;936:1-14.
14. Smith LEH, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997;276:1706-1709.
15. Higgins RD, Yan Y, Schrier BK. Somatostatin analogs inhibit neonatal retinal neovascularisation. Exp Eye Res. 2002;74:553-559.
16. Reiner PB, Laycock AG, Doll CJ. A pharmacological model of ischemia in the hippocampal slice. Neurosci Lett. 1990;119:175-178.
17. Mastrodimou N, Lambrou GN, Thermos K. Effect of somatostatin analogues on chemically induced ischaemia in the rat retina. Naunyn Schmiederbergs Arch Pharmacol. 2005;371:44-53.
18. 2+ current in the pituitary cell line AtT-20. Neuroscience. 1996;71:1073-1081.
19. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res. 2004;23:91-147.
20. Kouvidi E, Papadopoulou-Daifoti Z, Thermos K. Somatostatin modulates dopamine release in rat retina. Neurosci Lett. 2006;391:82-86.
21. 2A) receptors expression in the rabbit retina. Dev Brain Res. 2000;123:67080.
22. de Lecea L, Criado JR, Prospero-Garcia O, et al. A cortical neuropeptide with neuronal depressant and sleep-modulating properties. Nature. 1996;381:242-245.
23. 125I]Tyr10-cortistatin 14 labels all five somatostatin receptors. Naunyn Schmiederbergs Arch Pharmacol. 1998;357:483-489.
24. Forloni G, Lucca E, Angeretti N, Chiessa R, Vezzani A. Neuroprotective effect of somatostatin on nonapoptotic NMDA-induced neuronal death: role of cyclic GMP. J Neurochem. 1997;68:319-327.
25. Braun H, Schulz S, Becher A, Schroder H, Hollt V. Protective effects of cortistatin (CST-14) against kainate-induced neurotoxicity in rat brain. Brain Res. 1998;803:54-60.
26. Rauca C, Schafer K, Hollt V. Effects of somatostatin, octreotide and cortistatin on ischaemic neuronal damage following permanent middle cerebral artery occlusion in the rat. Naunyn Schmiedebergs Arch Pharmacol. 1999;360:633-638.
27. 2+ current modulated by cGMP-dependent protein kinase. Nature. 1994;369:336-339.
28. Mastrodimou N, Kiagiadaki F, Hodjarova M, Karagianni E, Thermos K. Somatostatin receptors (sst2) regulate cGMP production in rat retina. Regul Pept. 2006;133:41-46.
29. Radi R, Peluffo G, Alvarez MN, Navilliat M, Cayota A. Unraveling peroxynitrite formation in biological systems. Free Rad Biol Med. 2001;30:463-488.
30. Olesen S-P, Drejer J, Axelsson O, et al. Characterization of NS2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol. 1998;123:299-309.
31. Luo X, Lambrou GN, Sabel JA, Hicks D. Hypoglycemia induces general neuronal death, whereas hypoxia and glutamate transport blockade lead to selective retinal ganglion cell death in vitro. Invest Ophthalmol Vis Sci. 2001;42:2695-2705.
32. Izumi Y, Benz AM, Kurby CO, et al. An ex vivo rat retinal preparation for excitotoxicity studies. J Neurosci Methods. 1995;60:219-225.
33. Sall JW, Klisovic DD, O'Dorisio MS, Katz SE. Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells. Exp Eye Res. 2004;79:465-476.
34. Baldsiak-Figiel A, Lang GK, Kampmeier J, Lang GE. Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia. J Endocrinol. 2004;180:417-424.
35. Koesling D, Bohme E, Schultz G. Guanylyl cyclases, a growing family of signal-transducing enzymes. FASEB J. 1991;5:2785-2791.
36. Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res. 2003;93:96-105.
37. Yamamoto T, Bing RJ. Nitric oxide donors. Proc Soc Exp Biol Med. 2000;225:200-206.
38. Ando A, Yang A, Nambu H, Campochiaro PA. Blockade of nitric-oxide synthase reduces choroidal neovascularization. Mol Pharmacol. 1992;62:539-544.
39. Guimaraes CA, Assreuy J, Linden R. Paracrine neuroprotective effect of nitric oxide in the developing retina. J Neurochem. 2001;76:1233-1241.
40. Block ER, Herrera H, Couch M. Hypoxia inhibits L-arginine uptake by pulmonary artery endothelial cells. Am J Physiol. 1995;269:L574-580.
41. Zhakarikov SI, Block ER. Association of L-arginine transporters with fodrin; implication for hypoxic inhibition of arginine uptake. Am J Physiol. 2000;278:L111-L117.
42. Bates JN, Baker MT, Guerra R, Harrison DG. Nitric oxide generation from nitroprusside by vascular tissue: evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem Pharmacol. 1991;42(suppl):S157-S165.
43. Feelisch M, Noack EA. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol. 1989;139:19-30.
44. Schrammel A, Pfeiffer S, Schmidt K, Koesling D, Mayer B. Activation of soluble guanylyl cyclase by the nitrovasodilator 3-morpholinosydnonimine involves formation of S-nitrosoglutathione. Mol Pharmacol. 1998;54:207-212.
45. 2+ entry through store-operated channels. Brain Res. 2004;1023:243-252.
46. Kukovetz WR, Holzmann S. Mechanism of vasodilation by molsidomine. Am Heart J. 1985;109:637-640.
47. Trakranrungsie N, Will JA. Comparative vasodilation of peroxynitrite and 3-morpholinosydnonimine. Life Sci. 2001;69:2349-2359.
48. Estevez AG, Radj R, Barbeito I, Shin JT, Thompson J, Beckman JS. Peroxynitrite induces apoptosis in PC12 cells and alters responses to neurotrophic factors. J Neurochem. 1995;65:1543-1550.
49. Villa LM, Salas E, Darly-Usmar VM, Radomski MV, Moncada S. Peroxynitrite induces both vasodilatation and impaired vascular relaxation in the isolated perfused rat heart. Proc Natl Acad Sci USA. 1994;91:12383-12387.
50. McDonald LJ, Murad F. Nitric oxide and cyclic GMP signaling. Proc Soc Exp Biol Med. 1996;211:1-6.
51. Sakagami K, Kawamura H, Wu DM, Puro DG. Nitric oxide/cGMP-induced inhibition of calcium and chloride currents in retinal pericytes. Microvasc Res. 2001;62:196-203.
52. 2+ influx through voltage-dependent calcium channels. J Neurochem. 2001;76:341-350.
53. Okhuma S, Narihara H, Katsura M, Hasegawa T, Kuriyama K. Nitric oxide-induced [3H]GABA release from cerebral cortical neurons is mediated by peroxynitrite. J Neurochem. 1995;65:1109-1114.
54. Yu D, Eldred WD. Nitric oxide stimulates gamma-aminobutyric acid release and inhibits glycine release in retina. J Comp Neurol. 2005;483:278-291.
55. Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology. 2000;39:1483-1494.